PRLD · CIK 0001678660 · operating
Prelude Therapeutics is a clinical-stage precision oncology company developing targeted cancer medicines for patient populations with specific genetic alterations. The company focuses on protein degradation and transcriptional regulation as therapeutic mechanisms. Its pipeline includes PRT3789, a selective SMARCA2 degrader in development for advanced or metastatic solid tumors with loss of SMARCA4 function; PRT7732, an oral SMARCA2 degrader program; and PRT2527, a CDK9 inhibitor designed to target cancer-promoting transcriptional programs including MCL1, MYC, and MYB in advanced solid tumors.
The company operates as a clinical-stage entity without reported revenue streams, relying on capital financing to fund research and development activities. Prelude Therapeutics was incorporated in Delaware in 2016 and maintains its headquarters in Wilmington, Delaware. The organization operates with approximately 131 full-time employees and is publicly listed on Nasdaq, with a market capitalization of $0.2 billion.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-1.68 | $-1.68 | +16.8% | |
| 2023 | $-2.02 | $-2.02 | +17.2% | |
| 2022 | $-2.44 | $-2.44 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — |